

CURRICULUM VITAE

Michael Oscar Koch, M.D.

OFFICE ADDRESS:

Department of Urology
535 N. Barnhill Drive, Suite 420
Indiana University School of Medicine
Indianapolis, Indiana 46202-5289
317-274-7338

EDUCATION:

1977	A.B., Dartmouth College Hanover, New Hampshire
1981	M.D., Dartmouth Medical School Hanover, New Hampshire

HONORS:

Distinction in Engineering Major
Dartmouth College, 1977

Cum Laude, Dartmouth College, 1977

Alpha Omega Alpha Honor Medical Society
Dartmouth Medical School, 1981

Honorable Mention
American Urological Association Sponsored
Essay Contest in Laboratory Research, 1985

Member of European Association of Urology - AUA
Exchange Program 1996

LICENSURE:

Indiana
April 29, 1998

Tennessee #MD 17568 (Retired)
October 20, 1986

BOARD CERTIFICATION:

National Board of Medical Examiners, 1982
American Board of Urology, 1989
Recertification American Board of Urology, 1996

POSTGRADUATE MEDICAL TRAINING:

1981 - 1982	Internship, General Surgery Dartmouth-Hitchcock Medical Center Hanover, New Hampshire
1982 - 1983	Residency, General Surgery Dartmouth-Hitchcock Medical Center Hanover, New Hampshire
1983 - 1984	Surgical Research Fellowship Dartmouth Medical School Hanover, New Hampshire
1984 - 1986	Residency, Urology Vanderbilt University Medical Center Nashville, Tennessee
1986 - 1987	Chief Residency, Urology Vanderbilt University Medical Center Nashville, Tennessee

FACULTY APPOINTMENTS:

1998 - Present	Professor and Chairman Department of Urology Indiana University School of Medicine Indianapolis, Indiana
----------------	---

FACULTY APPOINTMENTS (Continued):

1995-1998	Vice Chairman Department of Urologic Surgery Vanderbilt University School of Medicine Nashville, Tennessee
1992-	Associate Professor Department of Urologic Surgery Vanderbilt University School of Medicine Nashville, Tennessee
1991	Interim Chairman Department of Urology Vanderbilt University School of Medicine Nashville, Tennessee
1987 - 1991	Assistant Professor Department of Urology Vanderbilt University School of Medicine Nashville, Tennessee

HOSPITAL APPOINTMENTS:

2001 – Present	Active Staff, Department of Urology St. Vincent's Hospital, Indianapolis, Indiana
1998 - Present	Chairman, Department of Urology Indiana University Medical Center
1998-present	Active staff at Rhodebush VA Medical Center, Clarian Health system, and Wishard Memorial Hospital in Indianapolis, Indiana
1987 - 1998	Chief of Urology, Department of Veteran's Affairs Medical Center, Nashville, Tennessee Nashville, Tennessee

PROFESSIONAL SOCIETIES:

American Board of Urology
American College of Surgeons
American Medical Association
American Urological Association
North Central Section of the American Urological Association
American Urological Association/AFUD Research Committee

Indiana State Medical Association
Vanderbilt Urology Society
Society of University Urologists
Society of Urologic Oncology
Society of Clinical Urologists
Society for Basic Urologic Research
Societe Internationale d'Urologie
European Association of Urology
American Society of Clinical Oncology

RESEARCH GRANTS:

- 1988 - 1990 Veterans Administration Research Advisory Group, Metabolic Complications of Urinary Diversion Through Intestinal Segments, \$60,500
- 1990 - 1993 Department of Veterans Affairs Medical Center, Merit Review Grant, Pathophysiology of Metabolic Alterations Following Urinary Diversion, \$128,800
- 1993 - 1996 Department of Veterans Affairs Medical Center, Merit Review Grant, Mechanisms of Potassium and Ammonium Absorption in Intestine, \$158,100.
- 1997 Gene Therapy Pilot Project, \$35,000.
- 1997 - 1998 National Cancer Institute Cancer Center Support Grant, Progression of prostate cancer to androgen independence: a role for the androgen receptor, \$15,000.
- 2001-2013 Selenium and Vitamin E Cancer Prevention trial (SWOG), \$2,500,000/12 years-Principal investigator

CLINICAL RESEARCH STUDIES:

1. A Randomized Comparative Trial of Casodex vs. Flutamide Used in Combination with Medical Castration in Patients with Untreated Metastatic Prostate Cancer. Sponsor - Zeneca Pharmaceuticals Group. **M.O. Koch** - Principal Investigator.
2. Phase II Study of Oral Bropiramine in Adult Patients with BCG-Resistant Bladder Carcinoma in situ or with Bladder Carcinoma in situ and Intolerance to BCG. Sponsor - The Upjohn Company. **M.O. Koch** - Principal Investigator.

3. Protocol for Use of Oral Bropiramine in Named Adult Patients with Bladder Carcinoma. Sponsor - The Upjohn Company. **M.O. Koch** - Principal Investigator.
4. Phase III Study of Oral Bropiramine vs Intravesical BCG in Adult Patients with BCG - Native Bladder Carcinoma in situ. Sponsor-The Upjohn Company. **M.O. Koch** - Principal Investigator.
5. Bropiramine (U-54461S) Oral Tablets: Phase II Study in Adults with Extravesicle Carcinoma in situ (CIS) BCG - Resistant Bladder CIS or Bladder CIS and Intolerance to BCG. Sponsor - The Upjohn Company. **M.O. Koch** - Principal Investigator.
6. Multicenter Randomized Phase II/III Trial of CD8(+) Tumor Infiltrating Lymphocyte Cell Therapy and Recombinant Interleukin-2 in Metastatic Renal Cell Cancer. Sponsor - Applied Immune Sciences. **M.O. Koch** - Principal Investigator.
7. A Double Blind, Parallel Group, Randomized Trial To Compare The Efficacy and Safety of Enoxaparin 40 mg SC QD and Unfractionated Heparin 5000 IU SC TID During 6-12 Days For Prevention of Deep Venous Thrombosis (DVT) in 800 Evaluable Patients After Planned Elective Curative Cancer Surgery. Sponsor - Rhone-Poulenc Rorer Pharmaceuticals. **M.O. Koch** - Principal Investigator.
8. Prostate Cancer Prevention Trial. Sponsor - National Cancer Institute, Division of Cancer Prevention and Control. **M.O. Koch** - Co-Principal Investigator.
9. D73P24: An Open Label, Non-Comparative Phase II Study of the Safety and Efficacy of Photodynamic Therapy (PDT) Utilizing PHOTOFRIN Polyporphyrin in the Treatment of Refractory Transitional Cell Carcinoma In Situ of the Urinary Bladder as an Alternative to Cystectomy. Sponsors - QLT Phototherapeutics, Inc and Lederle Laboratories. **M.O. Koch** - Co-Principal Investigator.
10. A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex) vs Placebo in Patients with Early Prostate Cancer. Sponsor - Zeneca Pharmaceuticals. **M.O. Koch** - Co-Principal Investigator.
11. Randomized Prospective Study Comparing Intermittent vs Continuous Androgen Deprivation with Lupron Depot in Clinical Stage D2 Prostate Cancer. Sponsor - TAP Holdings, Inc. **M.O. Koch** - Co-Principal Investigator.
12. A Phase III, Multi-Center Open-Label, Randomized Study of Abarelix-Depot vs Lupron Depot, in Patient with Prostate Cancer Who Are Candidates for Initial Hormonal Therapy. **M.O. Koch** - Principal Investigator.
13. A Multi-Center Study of Abarelix in Patients with Prostate Cancer in Whom GnRH Agonists are Contraindicated. **M.O. Koch** - Principal Investigator.

14. A Phase 3, Multicenter, Open-Label Randomized Study of Abarelix-Depot 100 mg. IM vs. Lupron Depot 7.5 mg IM in Patients Who are Candidates for Initial Hormonal Therapy. **M.O. Koch** - Principal Investigator.
15. Use of HIFU to treat Localized Prostate Cancer and Locally recurrent prostate cancer after radiation therapy or surgery. **M.O. Koch** - Principal Investigator. Focus surgery

PUBLICATIONS:

1. **Koch MO**, McDougal WS: Determination of renal function following urinary diversion through intestinal segments. *JOURNAL OF UROLOGY* 133:517-520, 1985.
2. **Koch MO**, McDougal WS: Chlorpromazine: adjuvant therapy for the metabolic derangements created by urinary diversion through intestinal segments. *JOURNAL OF UROLOGY* 134:165-169, 1985.
3. **Koch MO**, McDougal WS: Nicotinic acid: treatment for the hyperchloremic metabolic acidosis following urinary diversion through intestinal segments. *JOURNAL OF UROLOGY* 134:162-164, 1985.
4. **Koch MO**, McDougal WS: The pathophysiology of hyperchloremic metabolic acidosis following urinary diversions. *SURGERY* 98:561570, 1985.
5. McDougal WS, **Koch MO**: Accurate determination of renal function in patients with intestinal urinary diversions. *JOURNAL OF UROLOGY* 135:1175-1178, 1986.
6. **Koch MO**, McDougal WS: Genitourinary trauma in children. *TRAUMA QUARTERLY* 3:64-86, 1987.
7. McDougal WS, **Koch MO**, Shands C III, Price RR: Bony demineralization following urinary intestinal diversion. *JOURNAL OF UROLOGY* 140:853-855, 1988.
8. **Koch MO**, McDougal WS: Bone demineralization following ureterosigmoid anastomosis: an experimental study in rats. *JOURNAL OF UROLOGY* 140:856-859, 1988.
9. **Koch MO**, McDougal WS: Urologic causes of the acute abdomen. *SURGICAL CLINICS OF NORTH AMERICA* 68:399-413, 1988.
10. **Koch MO**, McDougal WS: Penile carcinoma: the case for primary lymphadenectomy. *CANCER TREATMENT RESEARCH* 46:55-64, 1989.
11. McDougal WS, **Koch MO**: Effect of sulfate on calcium and magnesium homeostasis following urinary diversion. *KIDNEY INTERNATIONAL* 35:105-115, 1989.
12. McDougal WS, **Koch MO**: Phallic reconstruction during exenterative surgery for invasive urethral carcinoma. *JOURNAL OF UROLOGY* 141:1201-1203, 1989.
13. Erb RE, Kaufman AJ, **Koch MO**, Dutt KS, Burnett LS, Winfield AC: Adenocarcinoma in a sigmoid conduit: report of a case. *UROLOGIC RADIOLOGY* 12:115-117, 1990.

14. Fleisher AC, Rao BK, **Koch MO**: New developments in transrectal sonography of the prostate. *CURRENT OPINION IN RADIOLOGY* 2:777-784, 1990.
15. Hill DE, McDougal WS, Stephens H, Fogo A, **Koch MO**: Physiologic and pathologic alterations associated with ultrasonically generated shock waves. *JOURNAL OF UROLOGY* 144:1531-1534, 1990.
16. **Koch MO**, Gurevitch E, Hill DE, McDougal WS: Urinary solute transport by intestinal segments: a comparative study of ileum and colon in rats. *JOURNAL OF UROLOGY* 143(6):1275-1279, 1990.
17. Hall MC, **Koch MO**, McDougal WS: Metabolic complications of urinary reconstruction with intestine: acid-base abnormalities. *UROLOGIC CLINICS OF NORTH AMERICA* 18(4):725-735, 1991.
18. **Koch MO**: Fluid and electrolyte management in urologic practice. *AUA UPDATE SERIES*, 1991.
19. **Koch MO**: Therasonics lithotripsy system. *SEMINARS OF UROLOGY* IX(4):275-278, 1991.
20. **Koch MO**, McDougal WS, Reddy PK, Lange PH: Metabolic alterations following continent urinary diversion through colonic segments. *JOURNAL OF UROLOGY* 145:270-273, 1991.
21. Concepcion RS, **Koch MO**, McDougal WS, Stewart JR, Merrill WH: Management of primary nonrenal parenchymal malignancies with vena caval thrombus. *JOURNAL OF UROLOGY* 145:243-247, 1991.
22. Stewart JR, Carey JA, McDougal WS, Merrill WH, **Koch MO**, Bender HW: Cavoatrial tumor thrombectomy using cardiopulmonary bypass without circulatory arrest. *ANNALS OF THORACIC SURGERY* May 51(5): 717-721, 1991.
23. **Koch MO**, Flora MD, McDougal WS: Urease and the acidosis of urinary intestinal diversion. *JOURNAL OF UROLOGY* 146:458-462, 1991.
24. **Koch MO**, McDougal WS, Thompson CO: Mechanisms of solute transport following urinary diversion through intestinal segments: an experimental study in rats. *JOURNAL OF UROLOGY* 146:1390-1394, 1991.
25. Follis HW, **Koch MO**, McDougal WS: Immediate management of prostatomembranous urethral disruptions. *JOURNAL OF UROLOGY* 147:1259-1262, 1992.

26. Fisher RE, **Koch MO**: Recognition and management of delayed disruption vesicourethral anastomosis in radical prostatectomy. *JOURNAL OF UROLOGY* 147:1579-1581, 1992.
27. **Koch MO**, McDougal WS, Hall MC, Hill DE, Braren HV, Donofrio MN: Long-term effects of urinary diversion: a comparison of myelomeningocele patients managed by clean intermittent catheterization and urinary diversion. *JOURNAL OF UROLOGY* 147:1343-1347, 1992.
28. Hall MC, **Koch MO**, McDougal WS: Mechanism of ammonium transport by intestinal segments following urinary diversion: evidence for ionized NH_4^+ transport via K^+ - pathways. *JOURNAL OF UROLOGY* 148:453-457, 1992.
29. Hall MC, **Koch MO**: Mechanism of NH_4^+ transport: inhibition by K^+ and Ba^{++} . *JOURNAL OF UROLOGY* 148:1285-1287, 1992.
30. Hall MC, **Koch MO**, Halter, Dahlstedt S: Morphologic and functional alterations of intestinal segments following urinary diversion. *JOURNAL OF UROLOGY* 149:664-666, 1993.
31. **Koch MO**, Coussens D: Impact of MVAC chemotherapy in patients with lymph node metastases from transitional cell carcinoma. *SEMINARS IN UROLOGY* 11(1):14-19, 1993.
32. Jones JS, **Koch MO**: Delayed rupture of type I posterior urethral injury: Case report. *JOURNAL OF UROLOGY* 149:1132-1134, 1993.
33. **Koch MO** and Smith JA, Jr: Local recurrence of squamous cell carcinoma of the penis. *UROLOGIC CLINICS OF NORTH AMERICA* 21(4):739-743, 1994.
34. **Koch MO**, Coussens D: Retrospective analysis of outcome in patients with nodal metastases from transitional cell carcinoma of the lower urinary tract. *UROLOGY* 43(3):317, 1994.
35. Superdock K, Dummer S, **Koch MO**, Gillian, Van Buren D, Nylander W, Richie R, Johnson HK: Disseminated histoplasmosis presenting as urinary tract obstruction in a renal transplant recipient. *AMERICAN JOURNAL OF KIDNEY DISEASE* 23(4):600, 1994.
36. **Koch MO**, Coussens D, Burnett LS: Ovarian remnant syndrome and ureteral obstruction: Medical Management. *JOURNAL OF UROLOGY* 152:158-160, 1994.
37. Brandell RA, Scaletsky R, **Koch MO**: Urinary solute transport by gastric mucosa: a comparison with ileum using a rat model. *UROLOGY* 44(3):343-347, 1994.

38. Pope JC, **Koch MO**, Bluth RF: Renal cell carcinoma in end-stage renal disease patients: a comparison of clinical significance in hemodialysis and renal transplant patients. *UROLOGY* 44(4):497-501, 1994.
39. Brandell RA, Hall MC, Braren HV, **Koch MO**: Exposure of intestinal segments to renacidin: analysis of metabolic and histologic effects using a rat model. *JOURNAL OF UROLOGY* 152:725-727, 1994.
40. **Koch MO**, Brandell RA, Lin D, Smith JA Jr.: The effect of sequential compression devices on intraoperative blood loss during radical prostatectomy. *JOURNAL OF UROLOGY* 152:1178-1179, 1994.
41. Robertson B, **Koch MO**, Kirchner F, Smith JA Jr.: Suboptimal treatment results with the Therasonics Lithotripter. *JOURNAL OF UROLOGY* 152:317-319, 1994.
42. Scaletscky R, **Koch MO**, Gray GF, Eckstein C, Bicknell S, Smith JA Jr.: Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. *JOURNAL OF UROLOGY* 152:129-131, 1994.
43. **Koch MO**, Smith JA Jr, Hodge EM, Brandell RA: Prospective development of a cost effective program for radical retropubic prostatectomy. *UROLOGY* 44(3):311-318, 1994.
44. **Koch MO** and Smith JA Jr: Local recurrence of squamous cell carcinoma of the penis. *UROLOGIC CLINICS OF NORTH AMERICA* 21:739-743, 1994.
45. Hall MC, **Koch MO**, Smith JA Jr.: Femoral neuropathy complicating urologic abdomino-pelvic procedures. *UROLOGY* 45:146-149, 1994.
46. **Koch MO**: Primary realignment of prostatomembranous urethral disruptions. *SEMINARS OF UROLOGY* XIII(1):38-44, 1995.
47. **Koch MO**: Cost Efficient Radical Prostatectomy. *SEMINARS OF UROLOGY* 13(3):197-203, 1995.
48. **Koch MO**: Orthotopic Neobladder Reconstruction after Radical Cystectomy. *TECHNIQUES IN UROLOGY* 1(4):197-203, 1995.
49. Kotkin L, **Koch MO**: Morbidity associated with non-operative management of extraperitoneal bladder injuries. *JOURNAL OF TRAUMA* 38(6):895-898, 1995.
50. **Koch MO**, Seckin B, and Smith JA, Jr: Impact of a collaborative care approach to radical cystectomy and urinary reconstruction. *JOURNAL OF UROLOGY* 154:996-1001, 1995.

51. **Koch MO** and Smith JA, Jr: Clinical outcomes associated with implementation of a cost efficient program for radical retropubic prostatectomy. *BRITISH JOURNAL OF UROLOGY* 76:28-33, 1995.
52. **Koch MO** and Smith JA, Jr: Cost-Containment in Urology. *UROLOGY* 46(1):14-26, 1995.
53. **Koch MO** and Smith JA, Jr: Influence of patient age and comorbidity on outcome of a collaborative care pathway after radical prostatectomy and cystoprostatectomy. *JOURNAL OF UROLOGY* 155:1681-1684, 1996.
54. Kotkin L and **Koch MO**: Impotence and incontinence after immediate realignment of posterior urethral trauma: Result of injury or management? *JOURNAL OF UROLOGY* Vol 155:1600-1603, 1996.
55. Pope J and **Koch MO**: Ureteral replacement with reconfigured colon substitute. *JOURNAL OF UROLOGY* 155:1693-1695, 1996.
56. Smith JA and **Koch MO**: Blood loss during radical retropubic prostatectomy: Is preoperative autologous blood donation indicated? *JOURNAL OF UROLOGY* 156:1077-1080, 1996.
57. Smith JA Jr and **Koch MO**: Collaborative Care Pathways: Impact on treatment costs and quality of care. *Urology International* 3:10-11, 1996.
58. Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lerner SP, **Koch MO**, and Schellhammer PF. Bopirimine immunotherapy of upper urinary tract carcinoma in situ. *UROLOGY* 48(1):28-32, 1996.
59. **Koch MO**: Commentary on ultrastructural changes in intestinal mucosa after diversion. *Journal of Urology - This Month in Investigative Urology* 156:2, 1996.
60. Chang SS and **Koch MO**. The use of an extended spiral bladder flap for the treatment of upper ureteral loss. *JOURNAL OF UROLOGY* 156:1981-1983, 1996.
61. **Koch MO**: Editorial on Health related quality of life among patients with metastatic prostate cancer. *Urology* 49(2):216-17, 1997
62. **Koch MO** and Smith JA. Low molecular weight heparin for prophylaxis of thromboembolic complications associated with radical prostatectomy. *Prostate Cancer & Prostatic Disease* 1:101-104, 1997.
63. Miller DA, **Koch MO**, Smith JA. Are we selecting patients for treatment of localized prostate cancer? Results of an actuarial analysis *Urology* 51(2):197-202, 1998.

64. **Koch, MO.** Androgen insensitive prostate cancer: Options for management. *AUA News* Vol 3(4): 35-41, 1998.
65. Nseyo UO, Jewett MG, Shumaker B, Klein E, Huben RP, **Koch M**, and Grose M. For the Bladder Photofrin Study Group. Photodynamic therapy utilizing Photofrin (Porfimer Sodium) as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the urinary bladder. *JOURNAL OF UROLOGY* 160(1): 39-44, 1998.
66. **Koch, MO.:** Cost-Effective Strategies for the Follow-up of Patients With Germ Cell Tumors. *Urol Clin North Am.* 1998 August;25(3):495-502
67. **Koch MO.** Improvements in radical retropubic prostatectomy. GUEST EDITOR: SEMINARS IN UROLOGIC ONCOLOGY. 18(1): 1, 2000.
68. **Koch MO.:** Management of the dorsal vein complex during radical retropubic prostatectomy. *SEMINARS IN UROLOGIC ONCOLOGY.* 18(1): 33-37, 2000.
69. Beck, SDW and **Koch MO:** Spiral Vesicle Ileal Neobladder. *CONTEMPORARY UROLOGY.* 12(4): 94-101, 2000.
70. Franke, JJ., Gilbert WB., Grier, J., **Koch, MO.**, Shyr, Y., Smith, JA, Jr.: Early Post-Prostatectomy Pelvic Floor Biofeedback. *Journal of Urology*, 2000 January; 163(1): 191-3.
71. **Koch MO.,** Foster, R., Bihle, R., and Wahle, G.: A Man With a Testis Mass. *AUA CD ROM Series*, February 2000.
72. Parekh, DJ., Gilbert, WB., **Koch, MO.**, Smith, JA, Jr., Continent Urinary Reconstruction Versus Ileal Conduit: A Contemporary Single-Institution comparison of Perioperative Morbidity and Mortality. *Urology*, 2000,, June; 55(6):852-5
75. Komhoff M, Guan Y, Shappell Hw, Davis L, Jack G, Shyr Y, **Koch MO**, Shappell SB, Bryer MD Enhanced Expression of Cyclooxygenase-2 in High Grade Human Transitional Cell Bladder Carcinomas. *Am J Pathol.* 2000 Jul;157(1):29-35.
74. **Koch MO,** Foster, RS, Bell, B, Beck, S, Cheng, L, Parekh, D, Jung, S. Characterization and Predictors of PSA Progression Rates After Radical Retropubic Prostatectomy. *JOURNAL OF UROLOGY*, Vol. 164, September 2000.
75. **Koch, MO,** Predicting Outcomes After Radical Prostatectomy. *Journal of Urology*, 2000, November;164(5):1601.
76. Kelley, MR., Cheng, L., Foster, RS., Tritt, R., Jiang, J., Broshears, J., **Koch, MO.**

Elevated and Altered Expression of the Multifunctional DNA Base Excision Repair and Redox Enzyme Ape1/Ref-1 in Prostate Cancer. *Clinical Cancer Research* Vol 7 824-830, April 2001.

77. Beck, SDW., **Koch, MO**. Spiral Ileal Neobladder Substitution with Orthotopic Ureteral Reimplantation: Early Results. *Tech Urol.* 2001 Sep;7(3):223-8.
78. Beck SD, Foster RS, Bihle R, **Koch MO**, Wahle GR, Donohue JP. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. *J Urol.* 2001 May;165(5):1517-20.
79. Jiang J, Neubauer BL, Graff JR, Chedid M, Thomas JE, Roehm NW, Zhang S, Eckert GJ, **Koch MO**, Eble JN, Cheng L. Expression of Group IIA Secretory Phospholipase A2 Is Elevated in Prostatic Intraepithelial Neoplasia and Adenocarcinoma. *Am J Pathol.* 2002 Feb;160(2):667-71.
80. Soergel TM, **Koch MO**, Foster RS, Bihle R, Wahle G, Gardner T, Jung SH. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. *J Urol.* 2001 Dec;166(6):2198-201.
81. Cheng L, Gu J, Ulbright TM, MacLennan GT, Sweeney CJ, Zhang S, Sanchez K, **Koch MO**, Eble JN. Precise micro dissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. *Cancer.* 2002 Jan 1;94(1):104-10.
82. Cheng L, Gu J, Eble JN, Bostwick DG, Younger C, MacLennan GT, Abdul-Karim FW, Geary WA, **Koch MO**, Zhang S, Ulbright TM. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas. *Am J Surg Pathol.* 2001 Oct;25(10):1231-6.
83. Jiang J, Ulbright TM, Younger C, Sanchez K, Bostwick DG, **Koch MO**, Eble JN, Cheng L. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. *Arch Pathol Lab Med.* 2001 Jul;125(7):921-3.
84. Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, **Koch MO**, Eble JN, Cheng L. Fas and Fas Ligand Expression is Elevated in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma. *Cancer.* 2002 Jul 95(7):296-300.

Jiang J, Neubauer BL, Graff JR, Chedid M, Thomas JE, Roehm NW, Zhang S, Eckert GJ, **Koch MO**, Eble JN, Cheng L. Expression of Group IIA Secretory Phospholipase A2 Is Elevated in Prostatic Intraepithelial Neoplasia and Adenocarcinoma. *Am J Pathol.* 2002 Feb;160(2):667-71.

85. Cheng L, Gu J, Ulbright TM, MacLennan GT, Sweeney CJ, Zhang S, Sanchez K, **Koch MO**, Eble JN. Precise micro dissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. *Cancer*. 2002 Jan 1;94(1):104-10.
86. Sanchez K, Sweeney C, Mass R, **Koch MO**, Eckert G, Geary W, Baldrige L, Zhang S, Eble J, and Cheng L. Evaluation of HER-2/neu Expression in Prostatic Adenocarcinoma. *Cancer* 2002 Oct 95(8):1-8.
87. Beck SD, Foster RS, Bihrlle R, Ulbright T, **Koch MO**, Wahle GR, Einhorn LH, Donohue JP. Teratoma in the orchiectomy specimen and volume of metastasis are Predictors of retroperitoneal teratoma in post chemotherapy nonseminomatous testis cancer. *J Urol*. 2002 Oct;168(4 Pt 1):1402-4. PMID: 12352402
88. Siqueira TM Jr, Kuo RL, Gardner TA, Paterson RF, Stevens LH, Lingeman JE, **Koch MO**, Shalhav AL. Major complications in 213 laparoscopic nephrectomy cases: the Indianapolis experience. *J Urol*. 2002 Oct;168(4 Pt1):1361-5. PMID: 12352393
89. Shalhav AL, Dabagia MD, Wagner TT, **Koch MO**, Lingeman JE. Training postgraduate urologists in laparoscopic surgery: the current challenge. *J Urol*. 2002 May;167(5):2135-7. PMID: 11956463
90. S Uchida T, Sanghvi NT, Gardner TA, **Koch MO**, Ishii D, Minei, Satoh T, Hyodo T, Irie A, Baba S. Transrectal high-intensity focused ultrasound for treatment of patients Stage T1b-2n0m0 localized prostate cancer: a preliminary report. *Urology*. 2002 Mar;59(3):394-8; discussion 398-9. PMID: 11880077
91. Fouts RL, Sandusky GE, Zhaug S, Eckert GJ, **Koch MO**, Ulbright ATM, Eble JN, Cheng L. Down-regulation fragile histidine triad expression in prostatic carcinoma. *Cancer* 97(6):1-6, 2003
92. Hong H, **Koch, MO**, Foster RS, Bihrlle R, Gardner TA, Fyfte J, Ulbright TM, Eble JN, Cheng L. Anatomic distribution of periprostatic adipose tissue: A mapping study of 100 radical prostatectomy specimens. *Cancer* 97(7): 106, 2003
93. **Koch, MO**, Nayee AH, Sloan J, Gardner T, Wahle GR, Bihrlle R, Foster RS. Early Catheter Removal After Radical Retropubic Prostatectomy: Long term follow-up. Accepted *J Urol* Feb 2003.
94. Brandli DW, **Koch, MO**, Foster RS, Bihrlle R, Wahle G, Gardner T, Jung SH. Biochemical disease free survival in patients with high PSA (20-100 ng/ml), Stage T1-2 No prostate cancer after radical prostatectomy. *Accept Brit J Urol* Feb 2003.

95. Hong H, **Koch, MO**, Foster RS, Bihrlé R, Gardner T, Fyffe J, Ulbright TM, Eble, Jn, Cheng L.
Anatomic Distribution of Periprostatic Adipose Tissue, A mapping study of 100 radical prostatectomy specimens.
Accept American Cancer Society Nov 2002
Art: C1070-02 Feb 3, 2003
96. Eichelberger L, **Koch, MO**, Daggy, J, Ulbright, T, Eble, John, Cheng, L
Predicting Tumor Volume in Radical Prostatectomy Specimens from Patients with Prostate Cancer Patients
American Society for Clinical Pathology July 2003.
97. Paterson RF, Ulbright TM, MacLennan GT, Zhang S, Pan C, Sweeney C, Moore CR, Foster RS, **Koch MO**, Eble JN, Cheng L: Molecular genetic alterations in the laser-capture microdissected stroma adjacent to bladder carcinoma. Art: C0359-03 Sept 2003 ASCO
98. Zeng, G, Hu Z, Kinch MS, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldrige LA, **Koch MO**, Ulbright TM, Eble JN, Cheng L: High Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia. Am J Pathol (in press)
99. Pan CX, Kinch MS, Kiener Pa, Langermann S, Serrero G, Sweeney CJ, Li L, Zhang S, Baldrige LA, Jones T, **Koch MO**, Ulbright TM, Eble JN, Cheng L: PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma) Clinical Cancer Research, February 15, 2004
99. Pan CX, Zhang J, Kinch MS, Zhang S, Li L, Baldrige LA, Wade C, **Koch MO**, Ulbright TM, Eble JN, Cheng L: Loss of 14-3-3 β in prostatic intraepithelial neoplasia and prostate adenocarcinoma(submitted)
100. Mosharafa, A, Foster, R S, Bihrlé, R, **Koch, MO**, Ulbright, T, Einhorn, L, Donohue, J: Does Retroperitoneal Lymph Node Dissection Have a Curative Role for Patients with Sex Cord-Stromal Testicular Tumors? American Cancer Society June 27 2003.
101. Cheng, L, **Koch, MO**, CCR Manuscript No. 031123-(Revision #1)-PC cell-derived growth factor (PCDGF), epithelin/granulin precursor) expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma C Pan, et al
102. Giesler, B, Given, B, Given, CW, Rawl, Susan, Monahan, P, Burns, D, Azzouz, F, Reuille, K, Weinrich, S, **Koch, MO**, Champion, V, Manuscript C-1453-04 Version 2- Improving the Quality of Life of Prostate Cancer Patients: A Randomized Trial

Testing the Efficacy of a Nurse-Driven Intervention. Cancer Journal(in press) Feb
2005

CHAPTERS:

1. **Koch MO**, McDougal WS: Genitourinary trauma in children. In: Marcus RE (ed). *Trauma in Children*. Rockville, Maryland: Aspen Publications, Inc., 1986.
2. **Koch MO**, Kirchner FK Jr: Disease of the genitourinary system in the elderly. In: Adkins RB, Scott HW JR (eds). *Surgical Care of the Elderly*. Baltimore: Williams & Wilkins, 1988, pp. 370-384.
3. **Koch MO**, McDougal WS: Ureter substitution. In: McDougal WS (ed). *Difficult Problems in Urologic Surgery*. Chicago, Illinois: *Yearbook Medical Publishers*, 1988, pp. 76-100.
4. **Koch MO**, McDougal WS: The case for primary lymphadenectomy in penile cancer. In: Lepor H (ed). *Urologic Oncology IV*. Boston: Kluwer Academic Publishers, 1989, pp. 55-64.
5. Watkins SE, **Koch MO**, McDougal WS: Genitourinary trauma. In: Rakel RE (ed). *Conn's Current Therapy*. Philadelphia, Pennsylvania: WB Saunders Company, 1990.
6. **Koch MO**, McDougal WS: Overview: Management of penile carcinoma. In: Whitehead D (ed). *Current Operative Urology*. Philadelphia, Pennsylvania: JP Lippincott, 1990.
7. **Koch MO**: Disorders of micturition. In: Jacobson HR, Striker GE, Klahr SK (eds). *The Principles and Practice of Nephrology*. Philadelphia, Pennsylvania: BC Decker, Inc., 1991, pp. 452-457.
8. **Koch MO**: Genitourinary trauma. In: Rakel RE (ed). *Conn's Current Therapy*. Philadelphia, Pennsylvania: WB Saunders Company, p. 621-625, 1992.
9. **Koch MO**: Urinary tract reconstruction with intestine. In: Stein, Caldamone, Smith(ed). *Practice of Urology*. April 1992.
10. **Koch MO**: Urinary diversion. In: Sant (ed). *Pathophysiologic Principles in Urology*. January 1994.
11. **Koch MO**: Laser therapy for invasive bladder cancer. In: Smith, Stein, Benson (ed). *Lasers in Urologic Surgery, Third Edition*. January 1994.
12. Follis HW, **Koch MO**, McDougal WS: Immediate management of prostatomembranous urethral disruptions. *Yearbook of Urology*, Mosby Yearbook, 1993.

13. **Koch MO**, McDougal WS: Primary realignment of traumatic complete prostatomembranous urethral disruption. In: McAninch JW (ed). *Traumatic and Reconstructive Urology*, Philadelphia: WB Saunders Co, pp. 385-391, 1996.
14. **Koch MO**: Disorders of micturition. Jacobson HR, Striker GE, Klahr S (eds). *The Principles and Practice of Nephrology, Second Edition*, St. Louis: Mosby Yearbook, pp. 315-321, 1995.
15. Hall MC and **Koch MO**. Perioperative fluid and electrolyte management. In: **Geriatric Urology** PD O=Donnell (ed), Little Brown & Co., pp. 69-81, 1994.
16. **Koch MO** and Smith JA, Jr: Natural history and surgical management of superficial bladder cancer stage (Ta/T1/Cis). In: Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS (eds). *Comprehensive Textbooks of Genitourinary Oncology*, Baltimore, Williams and Williams, pp. 405-415, 1996.
17. **Koch MO** and Smith JA, Jr: Surgical Management of Adrenal Tumors. In: *Principles and Practice of Genitourinary Oncology*, Raghavan D, Scher HI, Leibel SA, Lange P (eds), J.B. Lippincott, Philadelphia, pp. 993, 1996.
18. **Koch MO** and Smith JA, Jr: Radical Cystectomy in Men. *Atlas of the Urologic Clinics of North America*, W.B. Saunders Company, Philadelphia, Vol 5(2), October 1997.
19. **Koch MO**: The Incidental Renal Mass. AUA CD ROM Series, Decker Publishing. PMP #2, 1998.
20. **Koch MO**, Roth B: A man with voiding difficulties and back pain. AUA CD ROM Series, PMP #2, 1998.
21. **Koch MO**, Kirchner FK: Endoscopic realignment of prostatomembranous urethral disruptions. *Atlas of Urologic Clinics of North America*, W.B. Saunders Company, Philadelphia, Vol6(2), October 1998.
22. Beck SDW and **Koch MO**: Pheochromocytoma. *5 Minute Urology Consult, Section 2*, Lippincott Williams & Wilkins, Philadelphia, pp. 386-387, 2000.
23. Beck, SDW and **Koch MO**: Transurethral Resection Syndrome. *5 Minute Urology Consult, Section 2*, Lippincott Williams & Wilkins, Philadelphia, pp. 542-543, 2000.
24. Yerkes E and **Koch MO**. The Use of Intestine for Urinary Tract Reconstruction: Metabolic Implications and Management. *Urology* (Brazilian medical publication)(1996)

25. Baumgartner R, Wells N, **Koch MO**: Radical Prostatectomy. *Outcomes of Path-based, Collaborative Practice* (1997).
26. **Koch MO**, Smith JA, Miller D, Baumgartner B: Perioperative Management of Radical Prostatectomy: the Impact of Critical Care Pathways. *Management of Prostate Cancer* (In library, 1997/1998)
27. DeMarco, R., and **Koch, MO.**: Metabolic Alterations After Continent Urinary Diversion. *AUA Update Series*, (2000).

ABSTRACTS:

1. **Koch MO**, McDougal WS: Chlorpromazine: Adjuvant therapy for the metabolic derangement created by urinary diversion through intestinal segments. *JOURNAL OF UROLOGY* 133:132A. 1985. Presented at AUA 1985.
2. **Koch MO**, McDougal WS: Effect of urinary diversion on calcium metabolism and growth: an experimental study with rats. *JOURNAL OF UROLOGY* 137:209A, 1987. Presented at AUA, 1987.
3. McDougal WS, **Koch MO**: Metabolic consequences of urinary intestinal diversion. Presented at American Association of Genitourinary Surgeons, 1988.
4. Concepcion RS, **Koch MO**, McDougal WS, Richards WO: Detubularized intestinal segments in urinary tract reconstruction: why do they work? Presented at the AUA, *JOURNAL OF UROLOGY* 139:592, 1988.
5. McDougal WS, **Koch MO**, Flora MD: Ammonium metabolism in urinary intestinal diversion. Abstracts of the American Association of Genitourinary Surgeons. Presented 1989.
6. **Koch MO**, Hill DE, Gurevitch EJ, McDougal WS: Urinary solute transport by intestinal segments: a comparative study of ileum and colon in rats. Presented at AUA, *JOURNAL OF UROLOGY* 141:746, 1989
7. McDougal WS, Hill DE, Stephens WH, Price RR, **Koch MO**: Renal physiology and pathologic alterations following exposure of the kidney to ultrasonically generated shock waves. Presented at AUA, *JOURNAL OF UROLOGY* 141:689, 1989.
8. Stewart J, Carey JA, McDougal WS, Merrill WH, **Koch MO**, Hammon J, First WH, Bender HW: The role of cardiopulmonary bypass in arterial and inferior vena cava tumor thrombectomy. Presented at American Surgical Association, 1989.

9. Hill DE, Concepcion RS, **Koch MO**, Gishan FK, McDougal WS: The long-term effects of urinary storage of the canine intestine in lower tract reconstruction. Presented AUA, JOURNAL OF UROLOGY 141:1279, 1989.
10. **Koch MO**, McDougal WS, Flora MD: The role of urease in the acidosis of urinary intestinal diversion. Presented to AUA, 1990.
11. Follis HW, **Koch MO**, McDougal WS: Prostatomembranous urethral disruptions: the case for immediate realignment. Presented at AUA, JOURNAL OF UROLOGY 145:114, 1991.
12. **Koch MO**, McDougal WS, Hall MC, Hill DE, Braren HV, Donofrio MN: Long-term effects of urinary diversion: a comparison of myelomeningocele patients managed by clean intermittent catheterization and urinary diversion. Presented at AUA, JOURNAL OF UROLOGY 145:348, 1991.
13. **Koch, MO**, Hall MC, McDougal WS: Mechanisms of ammonium transported by intestinal segments following urinary diversion. Presented AUA, JOURNAL OF UROLOGY 145(4): 876, 1991.
14. Robertson JB, Hurd SD, **Koch MO**, Arteaga CL: Increased Phospholipase (PLC)- γ 1 activity in human non-small cell lung (NSCLC) and renal cell (RCC) carcinomas correlates with elevated EGF receptor levels. Presented at AACR, 1992.
15. **Koch MO**, Hall MC: Mechanism of ammonium transport: a study of ammonium transport kinetics and inhibition by potassium, and barium. Presented AUA JOURNAL OF UROLOGY 147(4):879, 1992.
16. Hall MC, **Koch MO**, Halter SA, Dahlstedt SM: Morphologic and functional changes of intestinal segments following urinary diversion. Presented AUA, JOURNAL OF UROLOGY 147(4):871, 1992.
17. Pope JC, **Koch MO**, Bluth RF: Renal cell carcinoma in end-stage renal disease patients: a comparison of clinical significance in hemodialysis and renal transplant patients. Presented SES AUA, April 1993.
18. **Koch MO**, Coussens DM: Impact of MVAC chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract. Presented AUA, JOURNAL OF UROLOGY 149(4):418, 1993.
19. Pope JC, **Koch MO**, Bluth RF: Renal cell carcinoma in end-stage renal disease patients: a comparison of clinical significance in hemodialysis and renal transplant patients. Presented AUA, JOURNAL OF UROLOGY 149(4):933, 1993.

20. France JJ, **Koch, MO**, Fisher R, Foley J: Management of chronic ureteral obstruction with double-J stents: immediate and long-term results. Presented AUA, JOURNAL OF UROLOGY 149(4):1117, 1993.
21. Brandell RA, Scaletscky R, **Koch MO**: Urinary solute transport by gastric mucosa: a comparison with ileum using a rat model. Presented AUA, JOURNAL OF UROLOGY 149(4):633, 1993.
22. Robertson JB, **Koch MO**, Kirchner FK, Smith JA: Suboptimal treatment results with the therasonics lithotripter. Presented AUA, JOURNAL OF UROLOGY 149(4):600, 1993.
23. Scaletscky R, **Koch MO**, Eckstein CW, Smith JA: Pathologic findings in prostate cancer detected because of PSA elevation. Presented AUA, JOURNAL OF UROLOGY 149(4):361, 1983.
24. Brandell RA, Hall MC, **Koch MO**, Braren V: Exposure of intestinal segments to citric acid-gluconodeltaaalacone-magnsium carbonate (renacidin): analysis of metabolic and histologic effects in a rat model. Presented AAP, Oct. 1993.
25. Kotkin L, Brandt T, **Koch MO**: Morbidity associated with non-operative management of extraperitoneal bladder ruptures. Presented AUA, JOURNAL OF UROLOGY 1241:317, 1994
26. **Koch MO**, Brandell R, Lin D, Smith JA: Effect of sequential pneumatic compression devices on blood loss during radical prostatectomy. Presented AUA, May 1994.
27. **Koch MO**, Brandell RA, Lin D, Smith JA: Design and implementation of a prospective study for cost containment after radical prostatectomy. Presented SES AUA, March 1994.
28. **Koch MO**, Brandell RA, Lin D, Smith JA: Effect of sequential pneumatic compression devices on blood loss during radical prostatectomy. Presented SES AUA, March 1994.
29. Schrum FF, **Koch MO**, Smith JA: Comparison of postoperative urinary continence after radical cystectomy and orthotopic neobladder versus radical prostatectomy. Presented SES AUA, March 1994.
30. Kotkin L, **Koch MO**: Impotence and incontinence after urethral disruption: results of the injury or its management? Presented AUA, JOURNAL OF UROLOGY 153:352, 1995.

31. **Koch MO**, Seckin B, Smith JA: Implementation of a collaborative care program for radical cystectomy: Impact on hospital charges and outcome analysis. Presented AUA, JOURNAL OF UROLOGY 153:343, 1995.
32. **Koch MO**, Seckin B, Smith JA: Implementation of a collaborative care program for radical cystectomy: impact on hospital charges and outcome analysis. Presented SES AUA, April 1995.
33. Kotkin L., **Koch MO**: Long-term results of primary urethral realignment. Presented SES AUA, April 1995.
34. Pope JC, **Koch MO**: The use of orthotopic neobladders in female patients. Presented SES AUA, April 1995.
35. Chang SS, **Koch MO**: Extended spiral bladder flap: treatment for upper ureteral obstruction. Presented SES AUA, April 1995.
36. Chang SS, **Koch MO**: Psoas flap is definitive treatment for radiation induced ureteral stricture disease. Presented SES AUA, April 1995.
37. Anthony C, **Koch MO**, Blackburn K, Case T, Steiner M: Growth factor expression in renal cell cancer. Accepted for presentation at AUA, Orlando, Florida, May 1996.
38. **Koch MO**, Smith JA: Blood loss during radical retropubic prostatectomy: Is preoperative autologous blood donation indicated? Accepted for presentation at AUA, Orlando, Florida, May 1996.
39. **Koch MO**, Chang SS, Smith JA: Low molecular weight heparin for prophylaxis of deep venous thrombosis after radical retropubic prostatectomy. Accepted for presentation at AUA, Orlando, Florida, May 1996.
40. **Koch MO**, Smith JA: Blood loss during radical retropubic prostatectomy: is preoperative autologous blood donation indicated? Accepted for presentation at SESAUA, LasCroabas, Puerto Rico, April 1996.
41. Johnson DR, Smith J, **Koch MO**, DeVore R, Blanke C, Johnson DH: Phase II trial of paclitaxel (P) and cisplatin © for metastatic or locally unrespectable ureotherlial cancer. Submitted for ASCO Annual Meeting, Philadelphia, PA, May, 1996.
42. **Koch MO**, Smith JA: Low molecular weight heparin for prophylaxis of deep venous thrombosis after retropubic prostatectomy. Accepted for presentation at the XIIIth Congress of the European Association of Urology in Paris, France, September 1996.

43. **Koch MO**, Smith JA: Blood loss during radical retropubic prostatectomy: is preoperative autologous blood donation indicated? Accepted for presentation at the XIIIth Congress of the European Association of Urology in Paris, France, September 1996.
44. **Koch MO**, Smith JA: Comorbidities and life expectancy in radical prostatectomy patients: Life insurance actuarial analysis. Accepted for presentation at the XIIIth Congress of the European Association of Urology in Paris, France, September, 1996.
45. Kasper S, **Koch MO**, Holt J, Steiner M, Matusik RJ, Smith JA: A rapid human prostate tumor assay for screening gene therapy vectors. Presented at the 1997 Annual Meeting of The Endocrine Society, Minneapolis, MN, June 1997.
46. Kasper S, Zhang JF, **Koch MO**, Smith JA, Matusik RJ: Gene therapy vectors for prostate cancer. Accepted for presentation at the 197 2nd World Congress on Urological Research, December 1997.
47. **Koch MO**, Todd RMF: The value of extensive, TRUS-guided prostate biopsy in patients with rising PSA and at least two previous negative biopsies. Accepted for presentation at the 1998 SES AUA, Birmingham, Alabama, April 1998.
48. Komhoff M, **Koch MO**, Davis L, Breyer M: Expression of cyclooxygenase-1 and -2 in human bladder cancer. Submitted for the 1998 AUA, San Diego, California, May 1998.
49. Borowsky AD, Gohanderakshan R, Holzbeierlein JM, Kasper S, **Koch MO**, Smith JA, Matusik RJ: Preoperative LH-RH agonist therapy in prostatic carcinoma: grading of pathologic alterations, androgen receptor localization, and disease progression. Submitted for the 1998 AUA, San Diego, California, May 1998.
50. Ead DN, **Koch MO**, Smith JA: Is invasive anesthetic monitoring necessary during radical prostatectomy? Submitted for the 1998 AUA, San Diego, California, May 1998.
51. Smith JA, **Koch MO**, Yerkes EE: Alprostadil for impotence after radical prostatectomy. Submitted for the 1998 AUA, San Diego, California, May 1998.
52. **Koch MO**, Holzbeierlein JM: Early results with the spiral vesicoileal pouch orthotopic neobladder. Accepted for presentation at the 1998 AUA, San Diego, California, May 1998.
53. Hatfield RW, **Koch MO**: Impact of injury severity and method of management in patients with prostatomembranous urethral disruptions. Accepted for publication at the 1998 AUA, San Diego, California, May 1998.

54. Zhang JF, Kasper S, **Koch MO**, Smith JA, Matusik RJ: Gene therapy vectors for prostate cancer. Accepted for presentation at the 1998 AUA, San Diego, California, May 1998.
55. **Koch MO**: State-of-the-art management of the radical prostatectomy patient. Presentation 1999 AUA, Dallas, Texas, May 1999.
56. **Koch MO**: Podium session on bladder reconstruction, augmentation, substitution, diversion (II), AUA, Dallas, Texas, May, 1999.
57. Kelly MR, Moore DH, Cheng L, Foster R, Michael H, Xu Yi, Parsons S, Tritt R, **Koch MO**: Plenary session on altered expression of the multifunctional DNA base excision repair and redox enzyme APE/REF-1 in ovarian and prostate cancers, AUA, Atlanta, Georgia, May, 2000.
58. **Koch MO**: Characterization of PSA recurrences after prostatectomy. AUA Atlanta, Georgia, May 2000.
59. **Koch MO**: Outcome of high PSA patient after prostatectomy. AUA Atlanta, Georgia, May 2000.
60. **Koch MO**: Does early PSADT accurately predict PSADT after prostatectomy? NCS of AUA, Phoenix, Arizona, 2000.
61. **Koch MO**: "My View of the Role of Laparoscopy in Kidney Cancer Surgery", The Cleveland Clinic, Cleveland, Ohio, February, 2001.
62. **Koch, MO**: "My Experience on Radical Prostatectomy", The Cleveland Clinic, Cleveland, Ohio, February, 2001
63. **Koch, MO**: "Economic Impact of Clinical Pathways". Third Great Lakes Urology Seminar, Detroit, Michigan, March, 2001.
64. **Koch, MO**: "Benchmarks for Radical Prostatectomy Techniques", Urological Oncology Update, Washington, DC, December, 2001.
65. **Koch, MO**: "Approaches for Large renal cell Carcinoma", Urological Oncology Update, Washington, DC, December, 2001.

INVITED LECTURES:

1. The Use of Bowel in Urology, AUA Continuing Medical Education Course, Atlanta, Georgia, 1988.

2. The Case of Early Repair of Prostatomembranous Urethral Disruptions, AUA Continuing Medical Education Course, Atlanta, Georgia, 1988.
3. Perioperative Care, ACS Continuing Medical Education Course, New Orleans, Louisiana, 1990.
4. Management of Benign Prostatic Conditions/Prostate Cancer, University of Tennessee Continuing Medical Education Course, Chattanooga, Tennessee, 1990.
5. Perioperative Care, AUA Continuing Medical Education Course, Toronto, Canada, 1991.
6. Symposium on Bladder Cancer, AUA, Toronto, Canada, 1993.
7. Metabolic Complication of Urinary Diversion. ACS, San Francisco, California, 1993.
8. Are we doing too Many Radical Prostatectomies? ACS, San Francisco, California, 1993.
9. Medical Staff, Tullahoma Hospital, "Prostate Carcinoma", Tullahoma, Tennessee, January 1994.
10. Renal Grand Rounds, "Renal Cell Carcinoma", Vanderbilt University Medical Center, Nashville, Tennessee, February, 1994.
11. Otolaryngology Grand Rounds, "Collaborative Pathways", Vanderbilt University Medical Center, Nashville, Tennessee, March 1994.
12. Ophthalmology Grand Rounds, "Collaborative Pathways", Vanderbilt University Medical Center, Nashville, Tennessee, April 1994.
13. AUA Post-Graduate Course on Urologic Oncology, San Antonio, Texas, 1994.
14. Urologic Oncology Course, Atlanta, Georgia, 1994.
15. Medical Staff at Shelbyville Hospital, "Urinary Incontinence in the Elderly: Diagnosis and Treatment", Shelbyville, Tennessee, April, 1994.
16. Oncology Grand Rounds, "Bladder Cancer", Vanderbilt University Medical Center, Nashville, Tennessee, June, 1994.
17. Medical Staff, Lebanon Hospital, "Prostate Cancer", Lebanon, Tennessee, June 1994.

18. Medical Grand Rounds, "Practical Applications of PSA", Vanderbilt University Medical Center, Nashville, Tennessee, February, 1995.
19. Tennessee Urology Association Annual Meeting, "Cost Containment Strategies in Urology", Nashville, TN, April, 1995.
20. Medical Staff, Jackson Hospital, "Collaborative Pathways", Jackson, Tennessee, August, 1995.
21. Birmingham Urology Journal Club, "Care of the Radical Prostatectomy Patient: Facts & Fiction", Birmingham, Alabama, September, 1995.
22. Surgery Grand Rounds, "The Testicular Mass", Vanderbilt University Medical Center, Nashville, Tennessee, September, 1995.
23. Twenty-fourth Annual Rhamy-Shelley Visiting Professorship, "Controversies in Urologic Trauma", Vanderbilt University Medical Center, Nashville, Tennessee, October, 1995.
24. Renal Grand Rounds, "Urinary Tract Reconstruction with Intestine", Vanderbilt University Medical Center, Nashville, Tennessee, January 1996.
25. Linking Practice Guidelines and Clinical Pathways with Outcome Management, "Radical Retropubic Prostatectomy: A Collaborative Care Pathway Approach to Patient Care", Sponsored by the University of Medicine and Dentistry and IBC Conferences, Scottsdale, Arizona, February, 1996.
26. Academic Physician Forum on Urology, "Microeconomics of Prostate Cancer for the University Urologist": Cancun, Mexico, February, 1996.
27. Texas Association of GU Surgeons, Nashville, Tennessee, April 1996.
28. Medical Staff, Fulton Hospital, Fulton, Kentucky, April, 1996.
29. Tenet Health System, Physician Advisory Board, "Development and Results from a Collaborative Care Program in Urology", Palm Springs, California, May, 1996.
30. American Urological Association Annual Meeting, "Collaborative Care Pathways", Orlando, Florida, May 1996.
31. The Upper Cumberland Medical Society's 102nd Annual Meeting, "Current Treatment of Prostate Cancer", Fairfield Glade, Tennessee, June 1996.
32. "Current Research in Urologic Cancer", Bowling Green, Kentucky, September, 1996.

33. Pathology Grand Rounds, "Update on Prostate Cancer", Vanderbilt University Medical Center, November, 1996.
34. "New Trials and Recent Results", Society of Urologic Oncology Annual Meeting, New Orleans, Louisiana, April, 1997.
35. "Plenary Session on Highlights of Cancer", American Urological Association Annual Meeting, New Orleans, Louisiana, April, 1997.
36. Post-Graduate Course, "Perioperative Management of Radical Prostatectomy", American Urological Association Annual Meeting, New Orleans, Louisiana, April, 1997.
37. Poster Session Moderator, "Management of Localized Prostate Cancer", American Urological Association Annual Meeting, New Orleans, Louisiana, April, 1997.
38. "Critical Pathways", Trover Foundation, Hopkinsville, Kentucky, May, 1997.
39. "Primary Realignment of Prostatomembranous Urethral Disruption Injuries: How I Do It", American Cancer Society Urologic Trauma Post-Graduate Course, Chicago, Illinois, October, 1997.
40. "prostate Cancer Screening", Primary Care Lecture Series, Vanderbilt University Medical Center, Nashville, Tennessee, October, 1997.
41. "The Diagnosis and Treatment of Superficial Bladder Carcinoma". Medical Oncology Division Seminar Series, Vanderbilt University Medical Center, Nashville, Tennessee, October, 1997.
42. "Orthotopic Neobladders in Females", 26th Annual Vanderbilt Urology Society Visiting Professorship and Rhamy-Shelley Lecture, Vanderbilt University Medical Center, Nashville, Tennessee, November, 1997.
43. "Radical Prostatectomy: Early and Late Results", the Lance Armstrong Urologic Oncology Meeting, Newport Beach, California, November, 1997.
44. "Urologic Problems in the Elderly", 7th Annual Spring Clinical Nephrology Meeting – Nephrology for the Primary Care Physician Program, Nashville, Tennessee, March, 1998.
45. Visiting Professor – Ohio State University, June, 1998.
46. Visiting Professor – Northwestern University, 1998.

47. "Radical Prostatectomy", the Lance Armstrong Urologic Oncology Meeting, Tysons Corner, Virginia, October, 1998.
48. Visiting Professor – university of Michigan, March 1999.
49. Visiting Professor, Montana Urological Society, Bozeman, Montana, September, 1999.
50. "Approaches to the Residual Retroperitoneal Mass Post-Chemotherapy", National Urology Oncology Update, New York, New York, November, 1999.
51. McDonald Lecturer, Phoenix Urological, November, 1999.
52. Practical Update on Urological Oncology, Deer Valley, Utah, January, 2000.
53. Visiting Professor, Southern Illinois University, February, 2000.
54. James H. McDonald Urologic Seminar, Scottsdale, Arizona, March, 2000.
55. "Clinical Problems in Urology", Northwestern University, Chicago, Illinois, March 2000.
56. "For Greater Use of Nerve Sparing Prostatectomy", University of Michigan, Great Prostate Shootout, Detroit, Michigan, September, 2000.
57. "Colovesical Fistulas", American College of Surgeons, October, 2000.
58. "Radical Cystectomy in the Male" North Central Section of the AUA, Phoenix, Arizona, November, 2000.
59. Culp Visiting Professor, Iowa Urological Society, September, 2000.
60. Visiting Professor, Albany Medical College, Albany , New York, June 2001
61. Loyola University Visiting Professor, 2003
62. Mayo Clinic Visiting Professor , 2003
63. Clyde Deming Visiting Professor, Yale University Medical School, Oct 2005
64. Michigan Urologic Invited Speaker, Oct 2005

OTHER RESPONSIBILITIES:

National Administrative

Reviewer for American Foundation Urologic Disease/National Kidney Foundation Grant Proposals, 1992-1995.

Independent Reviewer, VA Merit Review Program.

Member VA Merit Review Council, 1994-1995

Consultant to NIH on RFA on Minimally Invasive Surgery.

Member American Board of Urology/American Urological Association Joint Examination Committee, 1993-1997. - Task Force Chairman - 1996-1996.

Member Editorial Board, Patient Management Program series for AUA, Decker Electronic Publishing, 1996-present.

Chairman of Bylaws Subcommittee, Society of Urologic Oncology, 1996-1998.

Representative from the Southeastern Section of the American Urological Association to the AUA/AFUD Research Committee, 1997-1998.

Examiner for the Oral Examinations for the American Board of Urology, 1998 - Present.

Senior Member American Board of Urology Examination Committee, 1999-2003.

Chairman of American Board of Urology Examination Committee, 2000-2004.

Member of Executive Committee, Society of University Urologists.

Member of American Urological Association Education Council AUA

Representative to American College of Surgeons - Perioperative Care Committee. 1999 – 2000

Trustee of American Board of Urology 2004-present

President of Society of University Chairpersons and Program Directors 2005-2006

Reviewer for Investigative Section. *Journal of Urology*.

Reviewer for *Journal of Urology*.

Reviewer for *Urology*.

Regional Administrative

President of the Tennessee Urological Association - 1994-1995.

President Indiana Urological society

Member of Executive Committee, North Central Section of American Urological Association, 2001-2005.

Local Administrative

Veterans Administration Credentialing Committee, 1990-1996.

Veterans Administration Research and Development Committee, 1992-1995.

Tumor Committee, Vanderbilt Hospital, 1992-1995.
Laser Safety Committee, Vanderbilt Hospital, 1992-1995.

Chairman, Laparoscopy and Laser Ad Hoc Committee, Vanderbilt Hospital, 1991-1993.

Clinician Steering Committee, Vanderbilt Hospital, 1992-1993.

Cost Reduction Committee, Vanderbilt Hospital, 1993-1995.

Ambulatory Service Committee, Vanderbilt Hospital, 1993-1995.

Implementation Team Task Force Leader, Design Team Recommendations, 1995-1998.

One of five committees charged with redesigning hospital functions to improve Efficacy and Care.

Ad Hoc Member Hospital Medical Board, 1995-1998

Chief of Urology, Veterans Administration Hospital, 1987-1998.

OR Committee Member, Vanderbilt Hospital, 1991-1998.

Admissions Committee Member, Vanderbilt Medical School, 1993-1996.

Medical Records Committee Member, Vanderbilt Hospital, 1992-1998.

Chairman, Value Analysis Committee, 1993-1996.

Medical Director - Patient Care Improvement, 1996-1998.

President of the Vanderbilt Urology Society - 1994.

Chair of the Search Committee for CEO, IUMG-SC, Indiana University School of Medicine 2000

Chair of Search Committee for Chairman of Department of Surgery, Indiana University School of Medicine 2001

Chair of the IUMG-SC Business Affairs Committee 2001 – Present

Board member Indiana University medical Group-Primary care

Chairman of the Board of Faculty Practice Plan, Indiana University School of Medicine - 2001

Recent Invited Lectures

Alabama Urological Society- Summer 2002

AUA Urologic Oncology Course- Washington DC 2001

Great Lakes Urological- 2001

Cleveland Clinic Minimally Invasive Surgery course 2001

David A Culp Lecturer University of Iowa 2000

University of Michigan Visiting professorship- 2000

Montana Urological Society- 2000

April 24, 2006